ABUS · Arbutus Biopharma Corp · Executive Compensation
$4.67
+0.22 (+4.94%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$958.57M
Shares
197.85M
Volume · Oct 5
6.18M
Avg daily vol (3M)
4.58M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael McElhaugh | Former Interim President and Chief Executive Officer | $3,578,150 |
| Tuan Nguyen | Chief Financial Officer | $2,416,995 |
| David C. Hastings | Former Chief Financial Officer | $2,218,362 |
| Lindsay Androski | President and Chief Executive Officer | $1,369,013 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael McElhaugh | Former Interim President and Chief Executive Officer | $2,110,083 |
| David C. Hastings | Former Chief Financial Officer | $1,825,846 |
| Michael Sofia | Former Chief Scientific Officer | $1,820,054 |
| Karen Sims | M.D., Ph.D. Former Chief Medical Officer | $1,697,375 |
| Tuan Nguyen | Chief Financial Officer | — |
| Lindsay Androski | President and Chief Executive Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| William Collier | Former President and Chief Executive Officer | $3,385,984 |
| Elizabeth Howard | Former Executive Vice President, General Counsel, Chief Compliance Officer and Secretary | $1,842,723 |
| Michael McElhaugh | Former Interim President and Chief Executive Officer | $1,620,485 |
| Michael Sofia | Former Chief Scientific Officer | $1,614,688 |
| David C. Hastings | Former Chief Financial Officer | $1,556,806 |
| Karen Sims | M.D., Ph.D. Former Chief Medical Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| William Collier | Former President and Chief Executive Officer | $2,645,657 |
| Michael J. McElhaugh | Chief Operating Officer | $1,315,235 |
| Michael McElhaugh | Current Interim President and Chief Executive Officer | $1,315,235 |
| Michael Sofia | Chief Scientific Officer | $1,248,210 |
| Elizabeth Howard | Former Executive Vice President, General Counsel, Chief Compliance Officer and Secretary | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| William Collier | President and Chief Executive Officer | $3,215,289 |
| Michael Sofia | Chief Scientific Officer | $1,609,160 |
| David C. Hastings | Chief Financial Officer | $1,456,535 |
| Michael McElhaugh | COO | — |
| Michael J. McElhaugh | Chief Operating Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| William Collier | President and Chief Executive Officer | $2,728,324 |
| Michael Sofia | Chief Scientific Officer | $1,243,203 |
| Michael J. McElhaugh | Chief Business Officer | $1,087,791 |
| Michael McElhaugh | — | $1,087,791 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Mark J. Murray | Former President and Chief Executive Officer | $3,780,430 |
| William Collier | President and Chief Executive Officer | $2,334,185 |
| Michael Sofia | Chief Scientific Officer | $1,051,388 |
| David C. Hastings | Chief Financial Officer | $1,010,250 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Mark J. Murray | Former President and Chief Executive Officer | $2,527,885 |
| David C. Hastings | Chief Financial Officer | $1,452,867 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Roger Sawhney, MD | director | Appointed | 2026-05-27 |
| Joseph Bishop | director | Appointed | 2026-05-27 |
| Matthew Gline | director | Appointed | 2026-05-27 |
| Robert Alan Beardsley | director | Appointed | 2026-05-27 |
| Lindsay Androski, JD, MBA, CFA | director | Appointed | 2026-05-27 |
| Roger Sawhney | Board | Appointed | 2025-08-06 |
| Anuj Hasija | Board of Directors | Resigned | 2025-08-06 |
| David Hastings | Chief Financial Officer | Terminated | 2025-04-03 |
| Michael J. McElhaugh | Interim President and Chief Executive Officer | Resigned | 2025-02-25 |
| Lindsay Androski | chairperson of the Board | Appointed | 2025-02-25 |
| Lindsay Androski | President and Chief Executive Officer | Appointed | 2025-02-25 |
| Anuj Hasija | member of the Board | Appointed | 2025-02-25 |
| Matthew Gline | member of the Board | Appointed | 2025-02-25 |
| Robert Alan Beardsley | member of the Board | Appointed | 2025-02-25 |
| Joseph Bishop | member of the Board | Appointed | 2025-02-25 |
| Lindsay Androski | member of the Board | Appointed | 2025-02-25 |
| Melissa V. Rewolinski, Ph.D. | member of the Board of Directors | Resigned | 2025-02-25 |
| Keith Manchester, M.D. | member of the Board of Directors | Resigned | 2025-02-25 |
| James Meyers | member of the Board of Directors | Resigned | 2025-02-25 |
| Richard C. Henriques | member of the Board of Directors | Resigned | 2025-02-25 |
| Daniel Burgess | member of the Board of Directors | Resigned | 2025-02-25 |
| Michael J. McElhaugh | member of the Board of Directors | Resigned | 2025-02-25 |
| Frank Torti, M.D. | chairperson of the Board | Resigned | 2025-02-25 |
| Michael J. Sofia | Chief Scientific Officer | Retired | 2024-10-11 |
| Dr. Michael Sofia | Chief Scientific Officer | Retired | 2024-05-02 |